十二指腸液食道逆流(DER)モデルと胃十二指腸混合液食道逆流(GDER)モデルを手術的に作成した。手技安定後の生存率は、DER群：63%、GDER群：58%であり、手術作成モデルとしての手技は確立された。
術後40週でのバレット上皮の発現率は、DER群：71%、GDER群：83%、食道腺癌発生率は、DER群：29%、GDER群：33%であった。これまで我々が検討してきたラットモデルと比較して、発癌率は低率であり、組織学的にもおだやかな変化であった。
NFκB阻害剤であるパルテノライドを混餌投与したGDER群のバレット上皮発現率：69%、発癌率：15%と発現低下を認めた。
We produced the duodeno-esophageal reflux (DER) model and the gastroduodeno-esophageal reflux (GDER) model surgically. Survival rate after stabilization of surgical procedure was 63% in DER group and 58% in GDER group, respectively. The production procedure of mouse reflux esophagitis model was established.
The incidence of Barrett's epithelium was 71% in DER group and 83% in GDER group, respectively. The incidence of esophageal adenocarcinoma was 29% in DER group and 33% in GDER group in 40 weeks after surgery. The oncogenic rate was low and the histological change was mild in mouse model compared with rat models we have investigated.
Barrett epithelium was observed in 69% and esophageal adenocarcinoma was in 15% of mouse in the GDER group which were dietary administrated parthenolide, the NF-κB inhibitor. Chemopreventive effect of NF-κB inhibition in esophageal carcinogenesis caused by chronic inflammation was observed.
逆流性食道炎に伴う食道発癌における炎症反応制御と発癌抑制効果の関連
.png)
ME-PR-OYAMA-K-kaken 2015-4p.pdf
(99.96KB)
